Drug intelligence / Profile preview

gatifloxacin + prednisolone acetate

Development stage
Unknown
Lead developer
Allergan
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Gatifloxacin + prednisolone acetate is a fixed-dose combination ophthalmic medication used primarily to treat bacterial eye infections and to reduce inflammation in the eye, especially after surgery or in cases of uveitis, injury, or chemical burns. Gatifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. This results in bactericidal activity against both Gram-positive and Gram-negative bacteria. Prednisolone acetate is a corticosteroid that reduces inflammation by blocking the production of inflammatory mediators such as prostaglandins. The combination provides both antimicrobial action (from gatifloxacin) and anti-inflammatory effects (from prednisolone), making it effective for managing post-surgical or infectious ocular conditions[1][2][3][5][6].

Brand names
Gatiquin-PGat PPredzyNZ PredArogat-PAkrogat PVatiflo-PGate PGatiray P
Other names
gatifloxacin and prednisolone ophthalmic
02

Targets

GR (Glucocorticoid receptor)DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on gatifloxacin + prednisolone acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gatifloxacin + prednisolone acetate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call